Showcasing the Potential of Enhanced NK Cell Therapies for the Treatment of Neurodegenerative Disease: Introducing Troculeucel
Time: 12:00 pm
day: Conference Day Two - Track Two
Details:
- Outlining the mechanism of Troculeucel, a novel cell-based immunotherapy, for treating neurodegeneration
- Demonstrating early signs of clinical benefit in phase 1, leading to FDA fast track designation for moderate Alzheimer’s Disease and new IND for Parkinson’s Disease
- Highlighting future directions for Troculeucel in Frototemporal Dementia and post-stroke/TBI
